SEC Form 4 · accession 0001209191-18-022004
Audentes Therapeutics, Inc. · BOLD
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Suyash Prasad
Officer — Senior VP & Chief Med Officer
Period of report
Mar 26, 2018
Accepted (ET)
Mar 28, 2018 · 9:12 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001628738
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Mar 26, 2018 | M | 1,900 | $0.79 | A | 1,900 | D | |
| Common Stock | Mar 26, 2018 | S | 1,900 | $30.00 | D | 0 | D | |
| Common Stock | Mar 27, 2018 | M | 300 | $0.79 | A | 300 | D | |
| Common Stock | Mar 27, 2017 | S | 300 | $30.00 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F2 | $0.79 | Mar 26, 2018 | M | 1,900 | D | — | Feb 18, 2024 | Common Stock | 1,900 | 78,970 | D |
| Stock Option (right to buy)F2 | $0.79 | Mar 27, 2018 | M | 300 | D | — | Feb 18, 2024 | Common Stock | 300 | 78,670 | D |
Explanation of responses
- F1This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
- F2The option vested as to 25% of the total shares on February 18, 2015, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on February 18, 2018, subject to the reporting person's provision of service to the issuer on each vesting date.